PMID- 38039151
OWN - NLM
STAT- Publisher
LR  - 20231201
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Linking)
DP  - 2023 Dec 1
TI  - Antibody predictors of mortality and lung function trends in myositis spectrum 
      interstitial lung disease.
LID - kead638 [pii]
LID - 10.1093/rheumatology/kead638 [doi]
AB  - OBJECTIVES: The impact of autoantibody profiles on prognosis of idiopathic 
      inflammatory myositis associated interstitial lung disease (IIM-ILD) and myositis 
      spectrum ILD with Myositis Specific Antibodies (MSA) remains unclear. This 
      retrospective cohort study examines whether serological profiles are associated 
      with mortality and longitudinal lung function change. METHODS: Baseline 
      clinical/demographic characteristics and follow-up lung function of consecutive 
      adult patients with IIM-ILD or Interstitial Pneumonia with Autoimmune Features 
      (IPAF) positive for MSAs were extracted from three hospitals. Univariate and 
      multi-variate Cox-Proportional Hazards analyses were used to compare mortality 
      between autoantibodies. Regression models were used to analyse lung function 
      trends. RESULTS: Of 430 included patients, 81% met IIM criteria, 19% were 
      IPAF-MSA. On univariate analysis, risk factors associated with mortality included 
      higher age, Charlson Co-morbidity Index and CRP; and lower BMI, baseline TLCO% 
      and FEV1%. Compared to anti-MDA5-negativity, anti-MDA5-positivity (MDA5+) was 
      associated with high mortality in the first 3 months (HR 65.2. 95%CI 14.1, 
      302.0), while no significant difference was seen thereafter (HR 0.55, 95%CI 0.14, 
      2.28). On multi-variate analysis, combined anti-synthetase antibodies carried a 
      reduced risk of mortality (HR 0.63), although individually, mortality was reduced 
      in anti-Jo1 + (HR 0.61, 95%CI 0.4-0.87) and increased in anti-PL7+ patients (HR 
      2.07, 95%CI 1.44-2.99). Anti-MDA5+ was associated with slow improvement in %FVC 
      over the first 3 years, while anti-PL7+ was linked with a slow decline from 12 
      months onwards. CONCLUSIONS: Among autoantibody profiles in myositis spectrum 
      disorders, anti-MDA5+ and anti-PL7+ confer higher mortality risks. Survivors of 
      an early peak of mortality in anti-MDA5+ disease appear to have a favourable 
      prognosis.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the 
      British Society for Rheumatology.
FAU - Hannah, Jennifer R
AU  - Hannah JR
AD  - Department of Academic Rheumatology, King's College London, London, UK.
AD  - Deparment of Rheumatology, King's College Hospital, London, UK.
FAU - Lawrence, Alexandra
AU  - Lawrence A
AD  - Department of Respiratory Medicine, Guys and St Thomas' NHS Trust, London, UK.
FAU - Martinovic, Jennifer
AU  - Martinovic J
AD  - Department of Respiratory Medicine, Guys and St Thomas' NHS Trust, London, UK.
FAU - Naqvi, Marium
AU  - Naqvi M
AD  - Department of Respiratory Medicine, Guys and St Thomas' NHS Trust, London, UK.
FAU - Chua, Felix
AU  - Chua F
AD  - Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, 
      Guy's and St Thomas' NHS Foundation Trust, London, UK.
AD  - Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and 
      Lung Institute, Imperial College London, London, UK.
FAU - Kouranos, Vasileios
AU  - Kouranos V
AD  - Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, 
      Guy's and St Thomas' NHS Foundation Trust, London, UK.
AD  - Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and 
      Lung Institute, Imperial College London, London, UK.
FAU - Ali, Saadia Sasha
AU  - Ali SS
AD  - Department of Academic Rheumatology, King's College London, London, UK.
AD  - Department of Respiratory Medicine, Guys and St Thomas' NHS Trust, London, UK.
FAU - Stock, Carmel
AU  - Stock C
AD  - Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, 
      Guy's and St Thomas' NHS Foundation Trust, London, UK.
AD  - Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and 
      Lung Institute, Imperial College London, London, UK.
FAU - Owens, Cara
AU  - Owens C
AD  - Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, 
      Guy's and St Thomas' NHS Foundation Trust, London, UK.
FAU - Devaraj, Anand
AU  - Devaraj A
AD  - Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, 
      Guy's and St Thomas' NHS Foundation Trust, London, UK.
FAU - Pollard, Louise
AU  - Pollard L
AD  - Department of Respiratory Medicine, Guys and St Thomas' NHS Trust, London, UK.
AD  - Department of Rheumatology, University Hospital Lewisham, London, UK.
FAU - Agarwal, Sangita
AU  - Agarwal S
AD  - Department of Respiratory Medicine, Guys and St Thomas' NHS Trust, London, UK.
FAU - Atienza-Mateo, Belen
AU  - Atienza-Mateo B
AD  - Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, 
      Guy's and St Thomas' NHS Foundation Trust, London, UK.
AD  - Department of Rheumatology, Marques de Valdecilla University Hospital, Santander, 
      Spain.
FAU - Gonzalez-Gay, Miguel Angel
AU  - Gonzalez-Gay MA
AD  - Department of Rheumatology, IIS-Fundacion Jimenez Diaz, Madrid, Spain.
AD  - Department of Medicine and Psychiatry, University of Cantabria; Santander, Spain.
FAU - Patel, Amit
AU  - Patel A
AD  - Department of Academic Rheumatology, King's College London, London, UK.
FAU - West, Alex
AU  - West A
AD  - Department of Respiratory Medicine, Guys and St Thomas' NHS Trust, London, UK.
FAU - Tinsley, Kate
AU  - Tinsley K
AD  - Department of Respiratory Medicine, Guys and St Thomas' NHS Trust, London, UK.
FAU - Robbie, Hasti
AU  - Robbie H
AD  - Department of Academic Rheumatology, King's College London, London, UK.
FAU - Lams, Boris
AU  - Lams B
AD  - Department of Respiratory Medicine, Guys and St Thomas' NHS Trust, London, UK.
FAU - Wells, Athol U
AU  - Wells AU
AD  - Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, 
      Guy's and St Thomas' NHS Foundation Trust, London, UK.
AD  - Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and 
      Lung Institute, Imperial College London, London, UK.
FAU - Norton, Sam
AU  - Norton S
AD  - Deparment of Rheumatology, King's College Hospital, London, UK.
FAU - Galloway, James
AU  - Galloway J
AD  - Department of Academic Rheumatology, King's College London, London, UK.
AD  - Deparment of Rheumatology, King's College Hospital, London, UK.
FAU - Renzoni, Elisabetta A
AU  - Renzoni EA
AD  - Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, 
      Guy's and St Thomas' NHS Foundation Trust, London, UK.
AD  - Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and 
      Lung Institute, Imperial College London, London, UK.
FAU - Gordon, Patrick A
AU  - Gordon PA
AD  - Department of Academic Rheumatology, King's College London, London, UK.
AD  - Deparment of Rheumatology, King's College Hospital, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20231201
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
SB  - IM
OTO - NOTNLM
OT  - autoantibodies
OT  - idiopathic inflammatory myopathies
OT  - interstitial lung disease
OT  - mortality
OT  - myositis
OT  - progression
EDAT- 2023/12/01 18:42
MHDA- 2023/12/01 18:42
CRDT- 2023/12/01 12:43
PHST- 2023/09/14 00:00 [received]
PHST- 2023/11/06 00:00 [revised]
PHST- 2023/11/09 00:00 [accepted]
PHST- 2023/12/01 18:42 [medline]
PHST- 2023/12/01 18:42 [pubmed]
PHST- 2023/12/01 12:43 [entrez]
AID - 7457503 [pii]
AID - 10.1093/rheumatology/kead638 [doi]
PST - aheadofprint
SO  - Rheumatology (Oxford). 2023 Dec 1:kead638. doi: 10.1093/rheumatology/kead638.